硫酸氢吗啡酮 | 25333-57-7

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 中文名称: 硫酸氢吗啡酮
• 英文名称: Hydromorphone sulfate
• 英文别名: (4R,4aR,7aR,12bS)-9-hydroxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;sulfuric acid
• CAS: 25333-57-7
• 化学式: C17H21NO7S
• 分子量: 383.4
• InChiKey: JBBINZRUTLUBFR-NRGUFEMZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.98
• 重原子数：
  26
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  133
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• Preparation of Saturated Ketone Morphinan Compounds
  申请人：Wang Peter X.

  公开号：US20100261907A1

  公开（公告）日：2010-10-14

  The present invention provides processes for the preparation of saturated ketone morphinan compounds. In particular, the invention provides processes for the conversion of a morphinan comprising an allyl alcohol ring moiety into a morphinan comprising a saturated ketone ring moiety by an isomerization reaction catalyzed by an inorganic salt of a late transition metal.

  本发明提供了制备饱和羰基吗啡烷类化合物的方法。特别地，本发明提供了一种通过由晚期过渡金属的无机盐催化的异构化反应将含有烯丙醇环基团的吗啡烷转化为含有饱和羰基环基团的吗啡烷的方法。
• [EN] PREPARATION OF SATURATED KETONE MORPHINAN COMPOUNDS<br/>[FR] PRÉPARATION DE COMPOSÉS CÉTONE MORPHINANES SATURÉES
  申请人：MALLINCKRODT INC

  公开号：WO2010118275A1

  公开（公告）日：2010-10-14

  The present invention provides processes for the preparation of saturated ketone morphinan compounds. In particular, the invention provides processes for the conversion of a morphinan comprising an allyl alcohol ring moiety into a morphinan comprising a saturated ketone ring moiety by an isomerization reaction catalyzed by an inorganic salt of a late transition metal (II), (III).

  本发明提供了饱和酮型吗啡烷类化合物的制备方法。特别地，本发明提供了将含有烯丙醇环基团的吗啡烷转化为含有饱和酮环基团的吗啡烷的过程，该过程由晚期过渡金属（II），（III）的无机盐催化的异构化反应完成。
• Hydromorphone tablets
  申请人：ALZA CORPORATION

  公开号：EP1025845A2

  公开（公告）日：2000-08-09

  An oral hydromorphone composition for the management of pain comprising dosage form providing analgesia via the oral route over an extended period of time, comprising a therapeutic composition comprising 1 to 1000mg of hydromorphone; 25 to 500mg of carboxymethylcellulose of 10,000 to 300,000 mw as a polymeric carrier; a binder agent selected from at least one of the 1 to 50mg of poly (vinyl) pyrrolidone of 10,000 to 300,000 mw or 1 to 50mg of hydroxypropylcellulose or hydroxypropylalkylcellulose of 7,500 to 75,000 mw; and 0 to 10 mg of a lubricant.

  一种用于治疗疼痛的口服氢吗啡酮组合物，包括通过口服途径在较长时间内提供镇痛的剂型，其治疗组合物包括 1 至 1000 毫克氢吗啡酮；25 至 500 毫克 10,000 至 300,000 mw 的羧甲基纤维素作为聚合物载体；粘合剂，选自 1 至 50 毫克分子量为 10,000 至 300,000 的聚（乙烯基）吡咯烷酮或 1 至 50 毫克分子量为 7,500 至 75,000 的羟丙基纤维素或羟丙基烷基纤维素中的至少一种；以及 0 至 10 毫克润滑剂。
• Intrathecal hydromorphone solutions having improved stability
  申请人：PIRAMAL CRITICAL CARE LIMITED

  公开号：US10905685B2

  公开（公告）日：2021-02-02

  The present disclosure relates generally to a pharmaceutical solution comprising hydromorphone or a pharmaceutically acceptable salt thereof that is substantially free of buffer and optionally one or more other additives. The pharmaceutically acceptable salt may be hydromorphone hydrochloride. Also disclosed are methods for the manufacture and use of the solution.

  本公开内容一般涉及一种药液，它包含氢吗啡酮或其药学上可接受的盐，基本上不含缓冲剂和一种或多种其他添加剂。药学上可接受的盐可以是盐酸氢吗啡酮。还公开了该溶液的制造和使用方法。
• Compositions and methods for treating pain
  申请人：Ping H. Jeffrey

  公开号：US20050053656A1

  公开（公告）日：2005-03-10

  Compositions comprising of one or more analgesic tannates such as but not limited to hydrocodone tannate, codeine tannate, oxycodone tannate, oxymorphone tannate, morphine tannate, and hydromorphone tannate, alone or in combination with one or more additional active ingredients which are effective when administered for the treatment of pain.

  由一种或多种镇痛鞣酸盐（如但不限于鞣酸氢可酮、鞣酸可待因、鞣酸羟考酮、鞣酸羟吗啡、鞣酸吗啡和鞣酸氢吗啡酮）单独或与一种或多种额外的活性成分组合而成的复合物。